Join the club for FREE to access the whole archive and other member benefits.

Gregory Bailey

CEO at Juvenescence and chairman of Portage Biotech, Inc.

Dr. Gregory Bailey is chairman of Portage Biotech, Inc. a publicly traded drug development company and was previously managing partner of Palantir Group, Inc., a merchant bank specialising in biotech and intellectual property. He has over 15 years of experience in investment banking and has founded several companies. 

Along with comprehensive experience in healthcare, finance and medicine, Greg brings an extensive involvement in corporate governance. He has co-founded and served on multiple public and private company boards of directors, such as Palantir Group, Inc., Ascent Healthcare Solutions, VirnetX Inc. (VHC:AMEX), Portage Biotech Inc. (PTGEF: OTCBB), DuraMedic Inc., and MediqVentures Ltd.

Visit website:

See also: Company Juvenescence - Developing therapies against different aging related diseases.

Gregory Bailey News

Labiotech gathers feedback from European biotechs on Unity failure

Labiotech - 28-Aug-2020

General feeling that failures are bound to happen - but that their approaches can succeed


Juvenescence appoints a new CEO for its Epigenetic Division and Souvien Bio Ltd

Juvenescence - 11-Jun-2020

Goal is to develop drugs that target epigenetic mechanisms associated with neurodegeneration


Today's 50 year-olds may live another 100 years

Forbes - 26-Aug-2019

Good summary of some major investments in life extension companies